REPLY
18.6.2024 10:01:34 CEST | Business Wire | Press release
Reply, an international group specialised in creating new business models enabled by AI and Digital Media, introduces the jury that will be tasked with evaluating and selecting the best short films for the Reply AI Film Festival, an international competition open to all creatives eager to engage in creating a short film using AI tools.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618976841/en/
Reply presents the inaugural Reply AI Film Festival, an international competition where Artificial Intelligence (AI) serves not only as a catalyst for innovation in the realm of creative storytelling but also as a tool for fostering inclusivity among younger generations in video and film production. (Photo: Reply)
Judging the works submitted in the four competition categories - Narratives, Pilots, Documentaries, and Experimental - will be: Adam Kulick, producer of successful films such as Twilight, Wuthering Heights, and The Iron Lady, as well as a Sloan Fellow at Stanford University specialising in Generative AI; Caleb & Shelby Ward, co-founders of Curious Refuge, the first online community dedicated to directors using AI in their creations; Denise Negri, a journalist from SkyTg24 and Sky Arte, known for covering prestigious film events like the Academy Awards, Cannes Film Festival, and Venice Film Festival. Also participating are Filippo Rizzante, Chief Technology Officer at Reply; Flavio Natalia, director of Ciak and ciakmagazine.it, and an author and journalist for Ansa, Rai, and Sky; as well as the Canadian duo Vallée Duhamel, comprised of Julien Vallée and Eve Duhamel, who create unique short films for international brands using captivating images and videos that blend playful approaches with experimentation in new technologies such as artificial intelligence. Monica Riccioni, Chief Executive Officer of Think Cattleya, an advertising agency that has collaborated with numerous international directors and created campaigns for renowned global brands; Paul Trillo, a director and video artist known for his conceptual and visually inventive films, integrating new tools like AI with traditional techniques; and Rob Minkoff, co-director of The Lion King (1994) and animator and director of numerous films including Stuart Little, The Haunted Mansion, and Mr. Peabody & Sherman.
The jury will select the short films submitted to the competition via the platform aiff.reply.com by July 1, 2024, interpreting the theme of this first edition of the festival: Synthetic Stories, Human Hearts, a title that celebrates the convergence of human talent and artificial intelligence. In doing so, they will follow three main criteria: creativity, which refers to the innovative scope of cinematic language; craftsmanship, meaning the overall quality and value of the short film's production; and the impact of artificial intelligence, assessing how AI tools have contributed to one or more aspects of its creation.
Adam Kulick commented, "GenAI's integration into filmmaking processes opens up a new era of creativity and justifiable concerns. I'm hopeful that the fusion of human ingenuity and these rapidly evolving technologies produces groundbreaking work and new opportunities for the filmmaking community."
"We believe AI is going to act as a creative assistant in every part of the filmmaking pipeline. It’s going to allow for new stories to be told, it’s going to democratise the filmmaking industry and support filmmakers all around the world in telling their stories." said Caleb & Shelby Ward.
"AI is an increasingly valuable ally of creativity. We are truly delighted that such high-calibre figures in the film world have joined our initiative: a space to test AI as an ally of human creativity, but also an opportunity for young talents to immerse themselves in new technologies, acquire advanced skills, and bring new narratives to life," said Filippo Rizzante.
"I have always supported the potential of AI and believe that the combination of human and technological talent is not only possible but also enriches our work. This added value is something we at Think Cattleya greatly value and I am certain I will witness it during the screening of the short films in this competition," said Monica Riccioni.
"Specifically, AI's role should always be to assist the creatives, producers and crew working in film and not to replace them. It should not be used as a crutch or a shortcut for the creatively bankrupt. This is an opportunity for independent filmmakers to think out of the box and for smaller productions to create better, bolder and stranger films." confirmed Paul Trillo.
The ten best short films will be presented at a special premiere event organised by Reply, together with Mastercard, which has always been close to the world of cinema, connecting fans, performers and advocates to their passion. The event will take place during the days of the 81st Venice International Film Festival where the three overall winners will be announced.
To learn more about the Reply AI Film Festival, visit aiff.reply.com.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618976841/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
